307 related articles for article (PubMed ID: 27662198)
1. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Ford J; Thuro BA; Thakar S; Hwu WJ; Richani K; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(4):e82-e85. PubMed ID: 27662198
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
4. Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit.
Esmaeli B; Sagiv O
Int Ophthalmol Clin; 2019; 59(2):13-26. PubMed ID: 30908276
[No Abstract] [Full Text] [Related]
5. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK; Janik JE; Abu-Eid R; Mkrtichyan M; Khleif SN
Immunotherapy; 2015; 7(7):777-92. PubMed ID: 26250412
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
Longoria TC; Tewari KS
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
9. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
Harvey NT; Millward M; Macgregor K; Bucat RP; Wood BA
Am J Dermatopathol; 2016 Dec; 38(12):e159-e162. PubMed ID: 27870733
[TBL] [Abstract][Full Text] [Related]
13. Scleroderma Induced by Pembrolizumab: A Case Series.
Barbosa NS; Wetter DA; Wieland CN; Shenoy NK; Markovic SN; Thanarajasingam U
Mayo Clin Proc; 2017 Jul; 92(7):1158-1163. PubMed ID: 28599746
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
15. Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy.
Chang M; Lally SE; Dalvin LA; Orloff MM; Shields CL
Indian J Ophthalmol; 2019 Dec; 67(12):2071-2073. PubMed ID: 31755463
[TBL] [Abstract][Full Text] [Related]
16. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
18. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
[TBL] [Abstract][Full Text] [Related]
19. Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
Byrne EH; Fisher DE
Cancer; 2017 Jun; 123(S11):2143-2153. PubMed ID: 28543699
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
Hamid O
Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
